RU2018145776A3 - - Google Patents

Download PDF

Info

Publication number
RU2018145776A3
RU2018145776A3 RU2018145776A RU2018145776A RU2018145776A3 RU 2018145776 A3 RU2018145776 A3 RU 2018145776A3 RU 2018145776 A RU2018145776 A RU 2018145776A RU 2018145776 A RU2018145776 A RU 2018145776A RU 2018145776 A3 RU2018145776 A3 RU 2018145776A3
Authority
RU
Russia
Application number
RU2018145776A
Other languages
Russian (ru)
Other versions
RU2018145776A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2018145776A publication Critical patent/RU2018145776A/ru
Publication of RU2018145776A3 publication Critical patent/RU2018145776A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2018145776A 2016-05-25 2017-05-25 Комбинированные терапии модуляторами фарензоидного х-рецептора (fxr) RU2018145776A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662341487P 2016-05-25 2016-05-25
US201662341482P 2016-05-25 2016-05-25
US62/341,482 2016-05-25
US62/341,487 2016-05-25
PCT/US2017/034564 WO2017205684A1 (en) 2016-05-25 2017-05-25 Combination therapies with farnesoid x receptor (fxr) modulators

Publications (2)

Publication Number Publication Date
RU2018145776A RU2018145776A (ru) 2020-06-26
RU2018145776A3 true RU2018145776A3 (cg-RX-API-DMAC10.html) 2021-03-01

Family

ID=60412964

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018145776A RU2018145776A (ru) 2016-05-25 2017-05-25 Комбинированные терапии модуляторами фарензоидного х-рецептора (fxr)

Country Status (13)

Country Link
US (1) US20200397798A1 (cg-RX-API-DMAC10.html)
EP (1) EP3463373A4 (cg-RX-API-DMAC10.html)
JP (1) JP2019517478A (cg-RX-API-DMAC10.html)
KR (1) KR20190040936A (cg-RX-API-DMAC10.html)
CN (1) CN109843298A (cg-RX-API-DMAC10.html)
AU (1) AU2017270221A1 (cg-RX-API-DMAC10.html)
BR (1) BR112018073460A2 (cg-RX-API-DMAC10.html)
CA (1) CA3025007A1 (cg-RX-API-DMAC10.html)
IL (1) IL263179A (cg-RX-API-DMAC10.html)
MX (1) MX2018014024A (cg-RX-API-DMAC10.html)
RU (1) RU2018145776A (cg-RX-API-DMAC10.html)
SG (2) SG11201810290WA (cg-RX-API-DMAC10.html)
WO (1) WO2017205684A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019025228A2 (pt) * 2017-06-02 2020-06-23 Akarna Therapeutics, Ltd. Compostos bicíclicos fundidos
US11524029B2 (en) 2018-08-13 2022-12-13 Viscera Labs, Inc. Therapeutic composition and methods
US11590161B2 (en) 2018-08-13 2023-02-28 Viscera Labs, Inc. Therapeutic composition and methods
JP2022514731A (ja) * 2018-08-14 2022-02-15 アヴォリント 原発性硬化性胆管炎の処置方法
WO2020081766A1 (en) * 2018-10-18 2020-04-23 Avolynt Use of sglt2 inhibitors to treat primary sclerosing cholangitis
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN111825653A (zh) * 2019-04-19 2020-10-27 安道麦马克西姆有限公司 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途
CA3154488A1 (en) 2019-08-23 2021-03-04 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
CA3154391A1 (en) 2019-09-12 2021-03-18 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
EP4061357A4 (en) * 2019-11-22 2024-01-10 Avolynt Use of sglt2 inhibitors to treat primary billiary cholangitis
IL296100A (en) * 2020-03-11 2022-11-01 Dong A St Co Ltd A medicinal preparation for the prevention or treatment of non-alcoholic steatohepatitis
US11478533B2 (en) 2020-04-27 2022-10-25 Novo Nordisk A/S Semaglutide for use in medicine
US20220034871A1 (en) * 2020-07-31 2022-02-03 Daiichi Sankyo Company, Limited Methods for administering pexidartinib
PE20231096A1 (es) 2020-08-25 2023-07-18 Lilly Co Eli Polimorfos de un inhibidor de ssao
US20240319210A1 (en) * 2020-12-18 2024-09-26 Human Metabolomics Institute, Inc. Application of neonatal biliary atresia biomarker and detection method for same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009387A2 (en) * 2003-07-23 2005-02-03 X-Ceptor Therapeutics Inc. Azepine derivatives as pharmaceutical agents
ATE526318T1 (de) * 2005-12-19 2011-10-15 Glaxosmithkline Llc Farnesoid-x-rezeptor-agonisten
EP4137137A1 (en) * 2010-05-26 2023-02-22 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
AU2015314830B2 (en) * 2014-09-12 2021-01-07 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
CA2968434A1 (en) * 2014-11-21 2016-05-26 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
RU2021107054A (ru) * 2015-03-26 2021-03-31 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания

Also Published As

Publication number Publication date
MX2018014024A (es) 2019-08-29
BR112018073460A2 (pt) 2019-07-09
AU2017270221A1 (en) 2018-12-20
EP3463373A4 (en) 2020-04-22
WO2017205684A1 (en) 2017-11-30
CN109843298A (zh) 2019-06-04
SG10202011660RA (en) 2020-12-30
JP2019517478A (ja) 2019-06-24
KR20190040936A (ko) 2019-04-19
EP3463373A1 (en) 2019-04-10
CA3025007A1 (en) 2017-11-30
RU2018145776A (ru) 2020-06-26
US20200397798A1 (en) 2020-12-24
IL263179A (en) 2018-12-31
SG11201810290WA (en) 2018-12-28

Similar Documents

Publication Publication Date Title
BR112019002665A2 (cg-RX-API-DMAC10.html)
BR112018004986A2 (cg-RX-API-DMAC10.html)
BR112019008105A2 (cg-RX-API-DMAC10.html)
BR112019001429A2 (cg-RX-API-DMAC10.html)
BR212018070320U2 (cg-RX-API-DMAC10.html)
BR112019009203A2 (cg-RX-API-DMAC10.html)
BR112019011044B1 (pt) Compostos de pirazol substituído, seu uso, e composição farmacêutica
BR112019008501B1 (pt) Método realizado por um equipamento de usuário, método realizado por um nó de rede, equipamento de usuário, nó de rede, e, meios de armazenamento legíveis por computador
BR112019003116B1 (pt) Configuração de símbolo de rajada comum de uplink
BR112019001727B1 (pt) Método para comunicação sem fio realizado por um equipamento de usuário, método para comunicação sem fio realizado por uma estação-base, equipamento de usuário para comunicação sem fio, estação-base para comunicação sem fio, e memória
BR112019001236B1 (pt) Método para executar uma função suplementar para uma consulta de linguagem natural apresentada a um aplicativo de orientação de mídia interativa
BR112019000061B1 (pt) Comutação e modulação de splicing de pré-mrna compreendendo porções de arcabouço bicíclico, com características melhoradas para o tratamento de distúrbios genéticos
BR112018076493B1 (pt) Sistemas e métodos para detecção de posição de feixe de luz
BR112018073794B1 (pt) Partícula, método de geração da partícula, vacina ou composição farmacêutica
BR112018072681B1 (pt) Anticorpos anti-il-1r3 humanizados, fragmento ou derivado do mesmo, seu uso e composição farmacêutica
BR122026002225A2 (pt) Métodos para diagnosticar uma doença ou condição e para determinar dpp3 ativo em uma amostra de fluido corporal
BR122026002520A2 (pt) Célula, conjunto de vetores para expressar uma proteína de ligação a antígeno biespecífica em uma célula, conjunto de vetores, sistema, método, e, método para produção de uma proteína de ligação a antígeno
BR112019009373A2 (cg-RX-API-DMAC10.html)
BR112019006736A2 (cg-RX-API-DMAC10.html)
BR112019003108A2 (cg-RX-API-DMAC10.html)
CN303634890S (zh) 电视机(9600)
CN303627652S (zh) 汽车内饰面板(小纹理-凌云翼)
CN303640592S (zh) 带有资产管理信息系统界面的电脑(单位资产管理员版)
CN303621661S (zh) 手柄
CN303566220S (zh) 干手器(m-9998)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20210820